Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPersimmon Regulatory News (PSN)

Share Price Information for Persimmon (PSN)

Share Price is delayed by 15 minutes
Get Live Data
1,078.50    26.00 (2.47%)
Bid:
1,071.00
Ask:
1,072.00
Spread: 1.00 (0.093%)
Market Cap: £3.46b
PSN Live PriceLast checked at - London Stock Exchange

Intraday Persimmon Share Chart

Q1 Trading Statement

25 Apr 2024 07:00

RNS Number : 9243L
Persimmon PLC
25 April 2024
 

 

25 April 2024

Q1 Trading Statement

 

Persimmon Plc is today providing an update on trading for the period from 1 January 2024 to 31 March 2024, ahead of its Annual General Meeting ("AGM") which is being held at 11.00am today in York.

 

Dean Finch, Group Chief Executive, commented:

 

"Persimmon has had a good start to the year and is on track to deliver growth in completions to between 10,000-10,500 for the full year. Our first quarter performance was in line with expectations, and we saw an improvement in sales rates alongside firm pricing. Trading over recent weeks has been encouraging with robust visitor numbers and enquiries, giving us confidence for the remainder of the year. Overall, our private forward order book is up 18% on the prior year with the embedded private average selling price ahead of the position at the start of the year. We are making good progress in expanding our outlet network and we will continue to position the business for success, maintaining our focus on quality and customer service, and converting our land holdings into active developments."

 

Q1 Highlights

 

Q1 2024

Q1 2023

New home completions

1,027

1,136

Net private sales per outlet1

0.66

0.62

Current forward sales position2

£1.75bn

£1.69bn

Of which private forward sales2

£1.14bn

£0.97bn

Land holdings (plots owned and under control)

c.82,500

c.86,400

 

1Net private sales per outlet of 0.61 excluding bulk sales (Q1 2023: 0.58)

2Excluding completions in Q1 and as at 25 April 2024 for 2024 figure, as at 26 April 2023 for 2023 figure.

 

Trading

The Group traded in line with expectations during the first quarter delivering a total of 1,027 homes (Q1 2023: 1,136 homes). This included 852 private homes (Q1 2023: 902 homes) and 175 Partnership homes (Q1 2023: 234 homes).

 

The net private sales rate per outlet was up 6% in the first quarter at 0.66, or 0.61 excluding bulk sales. Customer interest remains good, and our marketing campaigns continue to generate healthy traffic to sites and online, despite ongoing affordability constraints.

 

Overall pricing on reservations held firm in the first quarter, with incentives currently running around 4-5% on average. Our private forward sales position has increased to £1.14bn with a private average selling price of c.£283,000 up 6% since the position at the start of the year (31 December 2023: c.£266,100).

 

Land spend in the first quarter was £145m (Q1 2023: £173m) of which £96m related to the settlement of land creditors (Q1 2023: £131m). Our owned and under control land holdings stood at c.82,500 plots at 31 March 2024 (31 March 2023: c.86,400 plots) and the embedded margin of the land portfolio remains industry-leading.

 

Outlook

We are encouraged by the level of visitors to our sites and are making good progress in expanding our outlet network. We opened 28 gross outlets in the first quarter ending the period with 263 outlets, up 2% on the position at the start of the year. A further c.30 gross outlets are planned to open by the end of June as part of our ambition to build back to pre-Covid outlet levels over the medium term.

As previously noted, first-half performance will be subject to embedded build cost inflation and lower average selling prices, as reflected in the forward order book at the start of the year. This trend is expected to reverse in the second half, given the increase in the average selling price in the current forward order book and broadly neutral build cost inflation since the start of the year. We continue to expect growth in full year 2024 completions to between 10,000 and 10,500 completions with an operating margin in line with the prior year.

 

For further information please contact:

Victoria Prior, Group IR Director

Anthony Vigor, Group Director of Strategic Partnerships and External Affairs

Olivia Peters

Teneo

Persimmon Plc 

persimmon@teneo.com

Tel: +44 (0) 1904 642199

Tel: +44 (0) 7902 771 008

 

 

Appendices:

1. Quarterly performance

 

Q1 2024

Q1 2023

Variance

Completions (homes)

1,027

1,136

-10%

Private (homes)

852

902

-6%

Partnership (homes)

175

234

-25%

Net private sales rate1

0.66

0.62

+6%

FTB % (private completions)

28%

38%

-10ppts

 

1Net private sales per outlet of 0.61 excluding bulk sales (Q1 2023: 0.58)

 

 

25 April 2024

26 April 2023

Variance

2. Forward sales1

Value

Homes

Value

Homes

Value

Homes

Private

£1.14bn

4,030

£0.97bn

3,496

+18%

+15%

Partnership

£0.61bn

3,762

£0.72bn

4,715

-16%

-20%

Total

£1.75bn

7,792

£1.69bn

8,211

+4%

-5%

 

1Excluding completions in Q1 and as at 25 April 2024 for 2024 figure, as at 26 April 2023 for 2023 figure.

 

Cautionary statements

Some of the information in this document may contain projections or other forward-looking statements regarding future events or the future financial performance of Persimmon Plc and its subsidiaries (the Group). You can identify forward-looking statements by the terms such as "expect", "believe", "anticipate", "estimate", "intend", "will", "could", "may" or "might", the negative of such terms or similar expressions. Persimmon Plc (the Company) wishes to caution you that these statements are only predictions and that actual events or results may differ materially and as such undue reliance should not be placed on these statements. The Company does not intend to update these statements to reflect events and circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events. Many factors could cause the actual results to differ materially from those contained in projections or forward-looking statements of the Group, including among others, general economic conditions, the competitive environment as well as many other risks specifically related to the Group and its operations. Past performance of the Group cannot be relied on as a guide to future performance.

 

Please see the most recent Annual Report and Accounts of Persimmon plc and other disclosures through the Regulatory News Service ("RNS") for further details of risks, uncertainties and other factors relevant to the business and its securities.

 

The information in this trading statement is unaudited.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFFRSTISFIS
Date   Source Headline
1st May 20257:00 amRNSAGM Trading Statement
25th Apr 202510:54 amRNSHolding(s) in Company
25th Apr 20259:24 amRNSHolding(s) in Company
11th Apr 20254:22 pmRNSHolding(s) in Company
3rd Apr 202510:15 amRNSHolding(s) in Company
2nd Apr 202512:22 pmRNSHolding(s) in Company
1st Apr 202512:03 pmRNSTotal Voting Rights
31st Mar 20253:14 pmRNSDirector/PDMR Shareholding
27th Mar 202510:08 amRNSHolding(s) in Company
25th Mar 20253:14 pmRNSDirector/PDMR Shareholding
24th Mar 20253:35 pmRNSAnnual Report 2024 and Notice of AGM 2025
24th Mar 20252:24 pmRNSHolding(s) in Company
11th Mar 20257:00 amRNSFull Year Results
6th Mar 20252:06 pmRNSHolding(s) in Company
3rd Mar 20253:35 pmRNSHolding(s) in Company
3rd Feb 202512:26 pmRNSTotal Voting Rights
14th Jan 20257:00 amRNS2024 Trading Statement
2nd Jan 20251:00 pmRNSTotal Voting Rights
10th Dec 20243:47 pmRNSDirectorate Change
2nd Dec 20242:11 pmRNSBlock listing Interim Review
2nd Dec 202412:00 pmRNSTotal Voting Rights
6th Nov 20247:00 amRNSQ3 Trading Statement
5th Nov 20241:31 pmRNSHolding(s) in Company
1st Nov 20243:59 pmRNSTotal Voting Rights
1st Oct 20241:19 pmRNSTotal Voting Rights
24th Sep 202412:25 pmRNSDirector/PDMR Shareholding
2nd Sep 20241:44 pmRNSTotal Voting Rights
8th Aug 20247:00 amRNSHalf Year Results
1st Aug 20242:32 pmRNSTotal Voting Rights
23rd Jul 202410:28 amRNSDirectorate Change
1st Jul 20241:10 pmRNSTotal Voting Rights
19th Jun 20242:48 pmRNSDirector/PDMR Shareholding
3rd Jun 202412:33 pmRNSBlock listing Interim Review
3rd Jun 202411:08 amRNSTotal Voting Rights
23rd May 20247:00 amRNSConfirmation of CFO start date
1st May 20241:11 pmRNSTotal Voting Rights
30th Apr 20242:03 pmRNSDirectorate Change
25th Apr 20242:09 pmRNSResult of AGM
25th Apr 20247:00 amRNSQ1 Trading Statement
2nd Apr 20241:49 pmRNSTotal Voting Rights
28th Mar 202412:53 pmRNSDirector/PDMR Shareholding
25th Mar 20244:47 pmRNSDirector/PDMR Shareholding
25th Mar 20242:07 pmRNSAnnual Report 2023 and Notice of AGM 2024
12th Mar 20241:38 pmRNSDirector/PDMR Shareholding
12th Mar 20247:00 amRNSFull Year Results
11th Jan 20246:00 pmRNSDechra Pharmaceuticals
10th Jan 20247:00 amRNSTrading Statement
1st Dec 20234:48 pmRNSBlock listing Interim Review
1st Dec 20234:45 pmRNSTotal Voting Rights
17th Nov 202310:25 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.